Tuong Vi Nguyen

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Sagar Lonial, Rakesh Popat, Cyrille Hulin et al. · The Lancet Haematology · 2022 · 92 citations · Full text

Medicine, Hematology, Oncology +11

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment

Natalie J. Hannan, Fiona Brownfoot, Ping Cannon et al. · Scientific Reports · 2017 · 70 citations · Full text

Veterinary Medicine, Obstetrics, Pathobiology +17

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Meletios Α. Dimopoulos, Katja Weisel, Philippe Moreau et al. · Leukemia · 2020 · 61 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Sagar Lonial, Niels W.C.J. van de Donk, Rakesh Popat et al. · Journal of Clinical Oncology · 2019 · 49 citations

Medicine, Pharmacology, Pharmacotherapy +17

Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia

Tu’uhevaha J. Kaitu’u‐Lino, Fiona Brownfoot, Sally Beard et al. · PLoS ONE · 2018 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17